8-K
false000111148500011114852023-08-072023-08-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 07, 2023

 

 

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40690

94-3268801

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

100 Columbia

 

Aliso Viejo, California

 

92656

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

RXST

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 2.02 Results of Operations and Financial Condition.

On August 7, 2023, RxSight, Inc. (the Company) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this report:

 

Exhibit number

 

Description

99.1

 

Press Release dated August 7, 2023.

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document).

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

RxSight, Inc.

 

 

 

 

Date:

August 7, 2023

By:

/s/ Shelley Thunen

 

 

 

Name: Shelley Thunen
Title: Chief Financial Officer

 


EX-99.1

 

https://cdn.kscope.io/4fbd7ac3b2f38233e04ceac07bd4b86f-img261313502_0.jpg 

Exhibit 99.1

 

 

 

RxSight, Inc. Reports Second Quarter 2023 Financial Results

Aliso Viejo, Calif. (NASDAQ: RXST) – August 7, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2023.

Key Quarterly Highlights

Reported second quarter 2023 revenue of $20.8 million, an increase of 83% compared to the second quarter of 2022, reflecting:
The sale of 67 Light Delivery Devices (LDD™s), representing a 37% increase in unit sales compared to the second quarter of 2022 and expanding the installed base to 523 LDDs at the end of the quarter, representing a 78% increase compared to end of the second quarter of 2022; and
The sale of 12,622 Light Adjustable Lenses (LAL®s), representing a 134% increase in procedure volumes compared to the second quarter of 2022.
The company increased its full-year 2023 guidance range for revenue, gross margin and operating expense.

“This quarter’s performance marks our 10th consecutive period of solid, year-over-year quarterly revenue growth, reflecting the increasing number of doctors and patients who are selecting our novel LAL system for the precise, high-quality visual outcomes it provides,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “The LAL is the first and only lens that can be customized after cataract surgery, providing patients the opportunity to preview and adjust their vision to meet their specific needs and preferences. While the LAL is still in the early adoption phase, we believe it can ultimately occupy a leading position in the premium cataract market.”

Second Quarter Financial Results

In the second quarter of 2023, total revenue was $20.8 million, an increase of 83% compared to $11.4 million in the second quarter of 2022. Revenue growth was driven by a 36% increase in LDD revenue and a 132% increase in LAL revenue compared to the second quarter of 2022.

Gross profit for the second quarter of 2023 was $12.0 million or 58% of revenue, an increase of $7.2 million or 151% compared to gross profit of $4.8 million or 42% of revenue for the second quarter of 2022.


Total operating expenses for the second quarter of 2023 were $25.6 million, a 25% increase from $20.6 million in the second quarter of 2022, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL procedure volumes.

In the second quarter of 2023, the company reported a net loss of $(13.8) million, or $(0.40) per basic and diluted share, compared to net loss of $(16.7) million, or $(0.61) per basic and diluted share in the second quarter of 2022. Adjusted net loss in the second quarter of 2023 was $(9.5) million, or $(0.28)

 


 

https://cdn.kscope.io/4fbd7ac3b2f38233e04ceac07bd4b86f-img261313502_0.jpg 

per basic and diluted share, compared to an adjusted net loss of $(13.8) million, or $(0.50) per basic and diluted share in the second quarter of 2022.

Cash, cash equivalents and short-term investments as of June 30, 2023, were $147.1 million compared to $153.9 million at March 31, 2023. In the second quarter of 2023, the company raised approximately $19.4 million, net after fees, through the sale of common stock under its “at-the-market” (“ATM”) facility. During the second quarter of 2023, the company used these proceeds and cash reserves to reduce its outstanding debt by $20.0 million and pay associated accrued interest and fees.

Early in the third quarter of 2023, the company raised additional proceeds of approximately $11.9 million, net of fees, through the sale of common stock under its ATM facility. The company used these proceeds and cash reserves to pay off its remaining $20.0 million term loan balance as well as associated accrued interest and fees. Through the elimination of $40.0 million in debt in the second and third quarters of 2023, the company expects to reduce its annual interest expense by approximately $5.6 million.

Financial Outlook

Based on second quarter 2023 performance, the company increased its 2023 full-year revenue, gross margin and operating expense guidance as follows:

Revenue of $81.0 million to $86.0 million, representing implied growth of 65% to 75% compared to 2022, up from prior guidance of $79.0 million to $84.0 million
Gross margin in range of 58% to 60%, representing an implied increase of 32% to 36% compared to 2022, up from prior guidance of 56% to 58%
Operating expenses in the range of $106.0 million to $109.0 million, representing an implied increase of 25% to 29% compared to 2022, up from prior guidance of $105.0 million to $108.0 million.

Conference Call

On Monday, August 7, 2023, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2023 financial results. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended participants join ten minutes prior to the event start time to ensure the necessary audio applications are downloaded and installed. Instructions are provided (including a dial-in option).

About RxSight, Inc.

RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery enabling doctors to customize and deliver high-quality of vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

 


 

https://cdn.kscope.io/4fbd7ac3b2f38233e04ceac07bd4b86f-img261313502_0.jpg 

This press release contains forward-looking statements, including with respect to the Company’s revenue growth trends; the increasing number of doctors and patients who are selecting the Company’s novel LAL; the ability of the Company’s LAL to occupy a leading position in the premium cataract market; and the Company’s projected revenue, gross margin, and operating expenses for 2023. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

 

Company Contact:

Shelley B. Thunen

Chief Financial Officer

sthunen@rxsight.com

 

Investor Relations Contact:

IR@rxsight.com

 

 

 


 

https://cdn.kscope.io/4fbd7ac3b2f38233e04ceac07bd4b86f-img261313502_0.jpg 

 

RxSIGHT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS (UNAUDITED)

(In thousands, except share and per share amounts)

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

Sales

 

$

20,810

 

 

$

11,360

 

 

$

38,299

 

 

$

20,301

 

 

Cost of sales

 

 

8,795

 

 

 

6,572

 

 

 

15,919

 

 

 

11,752

 

 

Gross profit

 

 

12,015

 

 

 

4,788

 

 

 

22,380

 

 

 

8,549

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

18,239

 

 

 

14,388

 

 

 

34,492

 

 

 

28,008

 

 

Research and development

 

 

7,401

 

 

 

6,192

 

 

 

14,608

 

 

 

12,911

 

 

Total operating expenses

 

 

25,640

 

 

 

20,580

 

 

 

49,100

 

 

 

40,919

 

 

Loss from operations

 

 

(13,625

)

 

 

(15,792

)

 

 

(26,720

)

 

 

(32,370

)

 

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(1,568

)

 

 

(1,136

)

 

 

(3,075

)

 

 

(2,196

)

 

Interest and other income

 

 

1,777

 

 

 

196

 

 

 

3,168

 

 

 

242

 

 

Loss on extinguishment of term loan

 

 

(362

)

 

 

 

 

 

(362

)

 

 

 

 

Loss before income taxes

 

 

(13,778

)

 

 

(16,732

)

 

 

(26,989

)

 

 

(34,324

)

 

Income tax expense

 

 

26

 

 

 

 

 

 

27

 

 

 

4

 

 

Net loss

 

$

(13,804

)

 

$

(16,732

)

 

$

(27,016

)

 

$

(34,328

)

 

Other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) gain on short-term investments

 

 

(65

)

 

 

(76

)

 

 

19

 

 

 

(150

)

 

Foreign currency translation gain (loss)

 

 

1

 

 

 

(9

)

 

 

3

 

 

 

(13

)

 

Total other comprehensive (loss) income

 

 

(64

)

 

 

(85

)

 

 

22

 

 

 

(163

)

 

Comprehensive loss

 

$

(13,868

)

 

$

(16,817

)

 

$

(26,994

)

 

$

(34,491

)

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic & diluted

 

$

(0.40

)

 

$

(0.61

)

 

$

(0.82

)

 

$

(1.25

)

 

Weighted-average shares used in computing net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to common stock, basic & diluted

 

 

34,498,265

 

 

 

27,559,908

 

 

 

33,075,585

 

 

 

27,493,130

 

 

 

 


 

https://cdn.kscope.io/4fbd7ac3b2f38233e04ceac07bd4b86f-img261313502_0.jpg 

RxSIGHT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except share and per share amounts)

 

 

 

June 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

8,753

 

 

$

11,834

 

Short-term investments

 

 

138,340

 

 

 

93,968

 

Accounts receivable

 

 

13,295

 

 

 

10,956

 

Inventories

 

 

17,945

 

 

 

14,835

 

Prepaid and other current assets

 

 

2,112

 

 

 

2,962

 

Total current assets

 

 

180,445

 

 

 

134,555

 

Property and equipment, net

 

 

10,533

 

 

 

10,138

 

Operating leases right-of-use assets

 

 

3,174

 

 

 

3,943

 

Restricted cash

 

 

761

 

 

 

761

 

Other assets

 

 

348

 

 

 

767

 

Total assets

 

$

195,261

 

 

$

150,164

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,997

 

 

$

2,595

 

Accrued expenses and other current liabilities

 

 

10,588

 

 

 

12,672

 

Lease liabilities

 

 

1,980

 

 

 

1,970

 

Total current liabilities

 

 

16,565

 

 

 

17,237

 

Long-term lease liabilities

 

 

1,843

 

 

 

2,856

 

Term loan, net

 

 

19,589

 

 

 

40,169

 

Other long-term liabilities

 

 

76

 

 

 

 

Total liabilities

 

 

38,073

 

 

 

60,262

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Common stock, $0.001 par value, 900,000,000 shares authorized, 35,168,041 shares issued and
  outstanding as of June 30, 2023 and 28,268,389 shares issued and
  outstanding as of December 31, 2022

 

 

35

 

 

 

28

 

Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued
  and outstanding

 

 

 

 

 

 

Additional paid-in capital

 

 

730,274

 

 

 

636,001

 

Accumulated other comprehensive loss

 

 

(73

)

 

 

(95

)

Accumulated deficit

 

 

(573,048

)

 

 

(546,032

)

Total stockholders' equity

 

 

157,188

 

 

 

89,902

 

Total liabilities and stockholders' equity

 

$

195,261

 

 

$

150,164

 

 

 

 


 

https://cdn.kscope.io/4fbd7ac3b2f38233e04ceac07bd4b86f-img261313502_0.jpg 

Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (GAAP), we believe certain non-GAAP measures, including adjusted net loss, and adjusted net loss per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense and loss on extinguishment of debt because these expenses are non-cash in nature and we believe excluding these items provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Net Loss and Adjusted Net Loss Per Share

Adjusted net loss is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation and (ii) loss on extinguishment of term loan. We believe adjusted net loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

 

 


 

https://cdn.kscope.io/4fbd7ac3b2f38233e04ceac07bd4b86f-img261313502_0.jpg 

Reconciliations of net loss to adjusted net loss and the presentation of adjusted net loss per share, basic and diluted, are as follows:

 

RxSIGHT, INC.

GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED)

(In thousands, except share and per share amounts)

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss available to stockholders, basic and diluted

 

$

(13,804

)

 

$

(16,732

)

 

$

(27,016

)

 

$

(34,328

)

Add:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

3,955

 

 

 

2,904

 

 

 

7,250

 

 

 

5,553

 

Loss on extinguishment of term loan

 

 

362

 

 

 

 

 

 

362

 

 

 

 

Adjusted net loss available to common stockholders, basic and diluted:

 

$

(9,487

)

 

$

(13,828

)

 

$

(19,404

)

 

$

(28,775

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding, basic and diluted

 

 

34,498,265

 

 

 

27,559,908

 

 

 

33,075,585

 

 

 

27,493,130

 

Adjusted net loss per share, basic and diluted

 

$

(0.28

)

 

$

(0.50

)

 

$

(0.59

)

 

$

(1.05

)